Skip to content

Drug interactions

Deferasirox + Repaglinide

Severity: Major

Deferasirox and Repaglinide: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Deferasirox inhibits CYP2C8 and can substantially increase repaglinide exposure, raising the risk of hypoglycemia. The product label advises dose reduction and glucose monitoring when the two are combined.

What this interaction means in plain words

Deferasirox and Repaglinide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Deferasirox belongs to Miscellaneous; Repaglinide belongs to Endocrine.

Evidence level: High

Why it happens

Deferasirox inhibits CYP2C8, a key pathway for repaglinide clearance.

What to do

Avoid the combination if possible; otherwise reduce the repaglinide dose and monitor blood glucose closely.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Deferasirox and Repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Deferasirox with Repaglinide?

MediHelp rates the interaction as major. Deferasirox and Repaglinide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Deferasirox inhibits CYP2C8 and can substantially increase repaglinide exposure, raising the risk of hypoglycemia. The product label advises dose reduction and glucose monitoring when the two are combined.

How serious is the interaction between Deferasirox and Repaglinide?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination if possible; otherwise reduce the repaglinide dose and monitor blood glucose closely.

What other medicines interact with Repaglinide?

MediHelp also lists interactions of Repaglinide with, for example, Gemfibrozil, Clarithromycin, Clopidogrel. The full list is on the Repaglinide page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in